Dermatological
The German biotech hopes to start Phase IIb trials soon of the oral complement C5a inhibitor in the extremely competitive hidradenitis suppurativa market.
Phase II results evaluating the anti-TSLP drug bosakitug are expected in the fourth quarter. Aclaris is pitching the asset as having best-in-class potential in a currently open field.
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
The Spanish company has set up shop in Shanghai to be closer to current and future dermatology partners.
As the Belgian firm's blockbuster beats AbbVie's Skyrizi in a head-to-head psoriatic arthritis study.
The company is advancing tilrekimig into Phase III development based on positive Phase II efficacy data that suggest a potential improvement over biologic standard of care Dupixent.
The Swiss company predicted Nemluvio could generate peak sales of $4bn in in prurigo nodularis and atopic dermatitis.
Kyowa Kirin halts all trials with its OX40-targeting antibody rocatinlimab following Kaposi’s sarcoma cases and Amgen's recent return of the asset.
The drug’s launch for hidradenitis suppurativa has been particularly impressive.
With the ongoing launch of the chronic hand eczema therapy, and the addition of Spevigo, the Danish group has entered 2026 with strong momentum, its CEO Christophe Bourdon tells Scrip.
Following 52-week maintenance data showing sustained and deepening responses, Nektar plans to advance rezpegaldesleukin into Phase III development, targeting a 2029 BLA submission.
With mid-stage data showing a 33% improvement in EASI score at 12 weeks, Evommune’s IL-18 inhibitor EVO301 might have a bright future in atopic dermatitis.
Following the recent acceptance of a China NDA for first-in-class drug denifanstat for acne in China, Ascletis has announced positive topline results from an open-label Phase III trial focusing on the product’s long-term safety.
The Paris-headquartered giant has heralded data from two new Phase III trials of the anti-OX40L antibody but there are still concerns over its level of efficacy.
The US biotech has upsized its public offering to $175m after the success of soquelitinib in a very early trial for atopic dermatitis.
The inflammatory skin disease typically affects the anogenital area and the Denmark-headquartered firm has started a Phase III trial evaluating its chronic hand eczema in that space.
The Swiss biotech’s shares jumped by 27% after the US agency said another trial was not needed to submit sonelokimab.
The San Francisco, CA-based firm looks to keep its pipeline-in-a-product hopes alive for rezpeg with alopecia areata push.
The deal, which could be worth as much as $1.7bn, looks to use Relation's AI capabilities to power the discovery of potentially first-in-class immuno-dermatology targets.
CEO Christophe Bourdon tells Scrip that the phone is ringing as the Danish drugmaker aims to become ‘the go-to partner for anything in dermatology.’